医学
哮喘
科克伦图书馆
不利影响
荟萃分析
安慰剂
内科学
随机对照试验
相对风险
上呼吸道感染
呼吸道感染
系统回顾
梅德林
置信区间
呼吸系统
替代医学
病理
法学
政治学
作者
W. Shang,Guizuo Wang,Yan Wang,Dong Han
标识
DOI:10.1016/j.clim.2022.108960
摘要
This systematic review and meta-analysis was performed to determine the safety of long-term use of ICS in patients with asthma.A systematic search was made of PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of asthma with ICS, compared with non-ICS treatment (placebo or other active drugs), were reviewed.Eighty-six RCTs (enrolling 51,538 participants) met the inclusion criteria. Oral or oropharyngeal candidiasis (RR 2.58, 95% CI 2.00 to 3.33), and dysphonia/hoarseness (RR 1.56, 95% CI 1.31 to 1.85) were less frequent in the control group. There was no statistically significant difference in the risk of upper respiratory tract infection, lower respiratory tract infection, influenza, decline in bone mineral density, and fractures between the two groups.In addition to the mild local adverse events, the long-term use of ICS was safe in patients with asthma.
科研通智能强力驱动
Strongly Powered by AbleSci AI